<?xml version="1.0" encoding="UTF-8"?>
<ref id="B85">
 <label>85.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Van Der Meeren</surname>
    <given-names>O</given-names>
   </name>
   <name>
    <surname>Hatherill</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Nduba</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Wilkinson</surname>
    <given-names>RJ</given-names>
   </name>
   <name>
    <surname>Muyoyeta</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Van Brakel</surname>
    <given-names>E</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis</article-title>. 
  <source>N Engl J Med</source>. (
  <year>2018</year>) 
  <volume>379</volume>:
  <fpage>1621</fpage>â€“
  <lpage>34</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1803484</pub-id>
  <?supplied-pmid 30280651?>
  <pub-id pub-id-type="pmid">30280651</pub-id>
 </mixed-citation>
</ref>
